FDA Brief

Warning letters Drugs

FDA warning letter to

Distribuidora Lagunera del Norte S.A. de C.V.

High riskIssued Mar 23, 2021Posted Mar 30, 2021Center for Drug Evaluation and Research

Distribuidora Lagunera del Norte’s weper hand sanitizer, labeled 70% ethanol, tested at 28% and was refused at the U.S. border.

What happened

FDA tested a batch of weper Clean Solutions Hand Sanitizer that was detained and refused admission at the U.S. border. The product was labeled to contain 70% ethanol, but FDA found an average of only 28% v/v ethanol. FDA also cited it as an unapproved new drug and misbranded, and placed all drugs made by the firm on Import Alert 66-78 on March 10, 2021.

What FDA found

  1. A batch labeled to contain 70% ethanol contained an average of only 28% v/v ethanol, so its strength was below what the label claimed.

    FD&C Act section 501(c), 21 U.S.C. 351(c)
  2. The low ethanol level shows the firm’s quality assurance was not working under CGMP.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  3. The hand sanitizer was an unapproved new drug because it was not generally recognized as safe and effective and had no FDA-approved application.

    FD&C Act section 505(a), 21 U.S.C. 355(a); section 301(d), 21 U.S.C. 331(d)
  4. The label was false or misleading because it claimed 70% ethanol and displayed an FDA logo above the NDC number, suggesting FDA approval.

    FD&C Act section 502(a), 21 U.S.C. 352(a); 21 CFR 207.77(b)
  5. The product label lacked the required Drug Facts panel.

    FD&C Act section 502(c), 21 U.S.C. 352(c); 21 CFR 201.66
  6. The product was misbranded because it is a nonprescription drug subject to section 505G but did not meet that section’s marketing requirements and had no approved application.

    FD&C Act section 502(ee), 21 U.S.C. 352(ee); section 505G, 21 U.S.C. 355h

What FDA wants

FDA asks the company to respond in writing within 15 working days, explaining how the labeled 70% product contained 28% ethanol, listing raw materials and suppliers and U.S.-shipped batches with reconciliation and batch records, and describing corrective actions to prevent recurrence. FDA also recommends a qualified CGMP consultant.

Who should pay attention

  • clinics and doctor’s offices that buy hand sanitizer
  • U.S. importers and distributors of foreign drug products
  • manufacturers and brands relying on labeled alcohol content

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Macau-Union Pharmaceutical Limited

    Macau-Union Pharmaceutical failed CGMP and sold unapproved, misbranded Bamboo Pharmacy OTC pain rubs in the U.S.

    High risk
  2. ImprimisRx NJ

    FDA found insanitary sterile compounding and subpotent timolol-latanoprost eye drops at ImprimisRx NJ.

    High risk
  3. Shuzy Rock Inc.

    FDA warns Shuzy Rock Inc. of adulterated hand sanitizers made under insanitary conditions and found below labeled alcohol strength.

    High risk
  4. Guangzhou Zhongkebaishi Health Industry Co., Ltd.

    Guangzhou Zhongkebaishi's Hand Sanitizer Gel, labeled 75% ethanol, tested at 51% and was refused US import.

    High risk